Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
News|Articles|September 16, 2026
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead, Yasmeen Qahwash
These FAQs outline key recommendations and practical takeaways from the 2026 AUA Medical Management of Kidney Stones guideline amendment.
Advertisement
Advertisement
The American Urological Association’s (AUA’s) updated guideline on the medical management of
Related to this article
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
A recap of the FDA submissions and regulatory decisions in urology from October 2026.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Advertisement
Advertisement